Protein Kinase Inhibitors clinical trials

Studies by the year they started

15,690 studies that test it; most in 2021 (981); 36 more planned to start later

Who runs them

Industry 6,674 · Other 9,092

National Cancer Institute (NCI) (867) · Novartis Pharmaceuticals (543) · Pfizer (483) · M.D. Anderson Cancer Center (424) · AstraZeneca (323) · Eli Lilly and Company (253) · GlaxoSmithKline (209) · Memorial Sloan Kettering Cancer Center (182)

Studies

Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten.

Testing one of them · 15,766

• Extension Study of Infigratinib in Children With Achondroplasia (ACH)Enrolling by invitationPhase 2QED Therapeutics, a BridgeBio companyNCT05145010Written as Infigratinib
• Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic CholangiocarcinomaNot yet recruitingPhase 3Zhejiang Cancer HospitalNCT07691515Written as Lenvatinib
• Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 InhibitorNot yet recruitingPhase 2National Heart, Lung, and Blood Institute (NHLBI)NCT07796373Written as Nemtabrutinib
• Gematinib Combined With Lenvatinib for the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Protein Overexpression: A Prospective, Multicenter, Phase II Clinical StudyNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT07894367Written as Lenvatinib
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyRecruitingPhase 3Hoffmann-La RocheNCT05646862Written as Inavolisib
• Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular CarcinomaRecruitingPhase 2University of California, IrvineNCT04472767Written as Cabozantinib
• A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 2National Cancer Institute (NCI)NCT06124157Written as Dasatinib
• Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 DeficiencyRecruitingPhase 1National Cancer Institute (NCI)NCT06090669Written as imatinib
• Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingPhase 2Mayo ClinicNCT03516617Written as Acalabrutinib
• Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE TrialRecruitingPhase 1/2National Cancer Institute (NCI)NCT06811116Written as Sapanisertib
• Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 ChangeRecruitingPhase 2National Cancer Institute (NCI)NCT03191149Written as Osimertinib
• MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia VeraRecruitingPhase 3University of BirminghamNCT04116502Written as Ruxolitinib
• Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic LeukemiaRecruitingPhase 2National Cancer Institute (NCI)NCT03739814Written as Ponatinib
• Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic DisordersRecruitingPhase 2Carl AllenNCT04079179Written as Cobimetinib
• Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell LymphomaRecruitingPhase 2National Cancer Institute (NCI)NCT04002947Written as Acalabrutinib
• Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.RecruitingPhase 3Novartis PharmaceuticalsNCT06846281Written as Remibrutinib oral treatment
• Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney CancerRecruitingPhase 2National Cancer Institute (NCI)NCT04981509Written as Erlotinib
• A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN LossRecruitingPhase 2VA Office of Research and DevelopmentNCT05593497Written as Capivasertib
• A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque PsoriasisRecruitingPhase 3Bristol-Myers SquibbNCT04772079Written as Deucravacitinib
• MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05564390Written as Emavusertib

See all 15,766 studies that test one of the protein kinase inhibitors →